Harmony Biosciences Holdings, INC 10-Q quarterly reports

Harmony Biosciences announced robust Q2 2026 results, driven by significant net product revenue growth, strategic pipeline advancements, and effective cost management.

Harmony Biosciences reported a 16.6% increase in net product revenue for Q1 2026, driven by unit shipments and a price increase, while research and development expenses more than doubled due to significant upfront license fees.

Harmony Biosciences reported strong financial growth in Q3 2025, driven by WAKIX sales, while advancing its diverse neurological pipeline despite a Phase 3 setback for ZYN002.

Harmony Biosciences Holdings, Inc. reported significant revenue and net income growth for the second quarter and first half of 2025, driven by strong WAKIX sales and progress across its expanded neuroscience pipeline.

Harmony Biosciences Holdings, Inc. announces a 19.5% increase in net product revenue for Q1 2025, driven by increased WAKIX sales and a price increase.

Harmony Biosciences reported a 16.1% increase in net product revenue for the third quarter of 2024, alongside significant advancements in their clinical pipeline.

Harmony Biosciences reported a 28.8% increase in net product revenue for the second quarter of 2024, driven by higher sales volume of WAKIX and a price increase.

Harmony Biosciences reported a strong first quarter of 2024, with a significant increase in net product revenue and progress in its clinical development programs.